Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma

7 Sept 2016

Abstract excerpt

BACKGROUND: The prognostic value of aberrant DNA methylation of cell-free circulating DNA in plasma has not previously been evaluated in diffuse large B cell lymphoma (DLBCL). The aim of this study was to investigate if aberrant promoter DNA methylation can be detected in plasma from DLBCL patients and to evaluate this as a prognostic marker. Furthermore, we wanted to follow possible changes in methylation levels...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Epigenetics and DNA Methylation
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27610206
DOI: 10.1186/s13148-016-0261-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphomaPMID 27610206Read ↗

Hypermethylation of DAPK1 is an independent prognostic factor predicting survival in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Circulating Tumor DNA as a Biomarker of Treatment Response and Minimal Residual Disease in Diffuse Large B-Cell Lymphoma: A Literature ReviewSemantic proximity Read ↗

Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA.Semantic proximity Read ↗

DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphomaSemantic proximity Read ↗

Genomic signatures in plasma circulating tumor DNA reveal treatment response and prognostic insights in mantel cell lymphomaSemantic proximity Read ↗

Clinical significance of PCDH10 promoter methylation in diffuse large B-cell lymphomaSemantic proximity Read ↗

5-hydroxymethylcytosine Profilings in Circulating Cell-free DNA as diagnostic biomarkers for DLBCLSemantic proximity Read ↗

Semimethylation is a feature of diffuse large B-cell lymphoma, and subgroups with poor prognosis are characterized by global hypomethylation and short telomere lengthSemantic proximity Read ↗

Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes.Semantic proximity Read ↗

The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas.Semantic proximity Read ↗

Investigation of MGMT and DAPK1 methylation patterns in diffuse large B-cell lymphoma using allelic MSP-pyrosequencing.Semantic proximity Read ↗

A DNA Methylation-Based Test for Breast Cancer Detection in Circulating Cell-Free DNASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.